Mobocertinib FDA Approval Status
FDA Approved: No
Generic name: mobocertinib
Company: Takeda Pharmaceutical Company Limited
Treatment for: Non-Small Cell Lung Cancer
Mobocertinib is an oral tyrosine kinase inhibitor (TKI) in development for the treatment of adult patients with epidermal growth factor receptor (EGFR) exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC).
Development Timeline for mobocertinib
|Apr 27, 2021||Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.